NINGBO, China, Jan. 24, 2022 /PRNewswire/ -- The 6th Heterojunction Leading Mass Production and Supply Chain Supporting Cooperation International Forum...

PR Newswire

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

byAdmin

January 24, 2022

SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- Concept Medical Inc., focused on vascular intervention drug delivery devices, shares the latest status of...

PR Newswire

U POWER Released UP SUPER BOARD and UP SPACE, Two Blockbuster Products

byAdmin

January 24, 2022

SHANGHAI, Jan. 24, 2022 /PRNewswire/ -- With the theme of "Born for Free Car-Making", the first UP DAY officially launched...

PR Newswire

International Day of Education 2022: Allschool Keeps Remote Courses Fun and Engaging with Classpod, a One-Stop Online Learning Tool

byAdmin

January 24, 2022

SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- In celebration of International Day of Education on January 24, Allschool ("the Company"), a...

PR Newswire

Sanya Welcomes Travelers this Spring Festival with an Exciting Lineup of Cultural Activities

byAdmin

January 24, 2022

SANYA, China, Jan. 23, 2022 /PRNewswire/ -- As the world prepares to ring in the Year of the Tiger, the...

PR Newswire

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

byAdmin

January 23, 2022

-- Approximately 80% of 180 patients with recurrent glioblastoma (rGBM) in the Phase III clinical trial are expected to be...

PR Newswire

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022

byAdmin

January 23, 2022

SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company...